BioNTech (BNTX) Stock Looks Fully Valued As Sales Face Pressure
BioNTech (BNTX) Dropped, So What Is Driving Attention Now?
BioNTech May Be the Next Moderna. Even if it Isn’t, the Stock Is a Buy.
BioNTech To Acquire FDA Priority Review Voucher From Scholar Rock For $205M In Cash
HC Wainwright & Co. Maintains Buy on BioNTech, Lowers Price Target to $110
BioNTech SE 2026 Q3 - Results - Earnings Call Presentation
UBS Maintains Buy on BioNTech, Lowers Price Target to $125
Morgan Stanley Maintains Overweight on BioNTech, Lowers Price Target to $106
Wells Fargo Maintains Overweight on BioNTech, Lowers Price Target to $125
BioNTech Q3: Bristol Myers Revenue Masks A Narrowing Oncology Bet (Rating Downgrade)
Evercore ISI Group Maintains Outperform on BioNTech, Lowers Price Target to $110
BioNTech (BNTX) Enters First Global Phase 3 Trial For New Breast Cancer Combo
BioNTech SE (BNTX) (Q3 2026) Earnings Call Highlights: Oncology Pipeline Momentum Builds as ...
BioNTech Q3 Earnings Call Highlights
BioNTech SE (BNTX) Q3 2026 Earnings Call Transcript
BioNTech Announces Third Quarter 2026 Financial Results and Corporate Update
BioNTech Q3 2026 Earnings Call Transcript
BioNTech Q3 Adj. EPS $2.03 Beats $0.97 Estimate, Sales $1.484B Beat $1.170B Estimate
BioNTech Narrows FY2026 Sales Guidance from $1.860B-$2.209B to $1.957B-$2.187B vs $2.020B Est
BioNTech (BNTX) Phase 3 Breast Cancer Win Comes With A Lung Safety Warning
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.